Biogen and Japan’s Eisai said they had positive results from a midstage study of an experimental Alzheimer’s drug, though experts said it was too soon to say the drug marks a real advance.
WSJ.com: What's News US, Wall Street Journal: Home US
Fri, 07/06/2018 - 12:50pm
Biogen and Japan’s Eisai said they had positive results from a midstage study of an experimental Alzheimer’s drug, though experts said it was too soon to say the drug marks a real advance.